Effect of SCG, 1,3-β-D-glucan from Sparassis crispa on the hematopoietic response in cyclophosphamide induced leukopenic mice

被引:83
作者
Harada, T
Miura, N
Adachi, Y
Nakajima, M
Yadomae, T
Ohno, N
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Immunopharmacol Microbial Prod, Hachioji, Tokyo 1920392, Japan
[2] Minhlth Co Ltd, Osato, Saitama 3600212, Japan
关键词
SCG; beta-glucan; hematopoietic response; interleukin-6; natural killer cell;
D O I
10.1248/bpb.25.931
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Sparassis crispa Fr. is an edible mushroom recently cultivable in Japan. it contains a remarkably high content of 6-branched 1,3-beta-D-glucan showing antitumor activity. Using ion-exchange chromatography, a purified beta- glucan preparation, SCG, was prepared. In this study, we examined the hematopoietic response by SCG in cyclophosphamide (CY)-induced leukopenic mice. SCG enhanced the hematopoietic response in CY induced leukopenic mice by intraperitoneal routes over a wide range of concentrations. SCG enhanced the hematopoietic response in CY-treated mice by prior or post administration. Analyzing the leukocyte population by flow cytometry, monocytes and granulocytes in the peritoneal cavity, liver, spleen and bone marrow (BM) recovered faster than in the control group. The ratio of natural killer cells and) gammadelta T cells in the liver, spleen and peritoneal cavity was also increased. In contrast, CD4(+) CD8(+) cells in the thymus were temporarily significantly decreased by the administration of SCG. Interleukin-6 (IL-6) production of CY+SCG-treated peritoneal exdated cells (PECs), spleen cells and bone marrow cells (BMCs) were higher than that of the CY-treated group. By in vitro culture of CY-treated PEC and spleen cells, IL-6 production was enhanced by the addition of SCG. These facts suggested the possibility that IL-6 might be a key cytokine for the enhanced hematopoietic response by SCG.
引用
收藏
页码:931 / 939
页数:9
相关论文
共 49 条
[1]
ADACHI Y, 1994, BIOL PHARM BULL, V17, P1554, DOI 10.1248/bpb.17.1554
[2]
AKAGAWA KS, 1988, J IMMUNOL, V141, P3383
[3]
Early signaling via inhibitory and activating NK receptors [J].
Bléry, M ;
Olcese, L ;
Vivier, E .
HUMAN IMMUNOLOGY, 2000, 61 (01) :51-64
[4]
Bordignon C, 1999, HAEMATOLOGICA, V84, P1110
[5]
UPDATE ON THE IMMUNOMODULATING ACTIVITIES OF GLUCANS [J].
DILUZIO, NR .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1985, 8 (04) :387-400
[6]
EYNDE BJ, 1997, CURR OPIN IMMUNOL, V9, P684
[7]
CLINICAL-EVALUATION OF SCHIZOPHYLLAN ADJUVANT IMMUNOCHEMOTHERAPY FOR PATIENTS WITH RESECTABLE GASTRIC-CANCER - A RANDOMIZED CONTROLLED TRIAL [J].
FUJIMOTO, S ;
FURUE, H ;
KIMURA, T ;
KONDO, T ;
ORITA, K ;
TAGUCHI, T ;
YOSHIDA, K ;
OGAWA, N .
JAPANESE JOURNAL OF SURGERY, 1984, 14 (04) :286-292
[8]
Health benefits of probiotics [J].
Goldin, BR .
BRITISH JOURNAL OF NUTRITION, 1998, 80 (04) :S203-S207
[9]
Hashimoto T, 1997, BIOL PHARM BULL, V20, P1006
[10]
Evidence that a transient enhancement of endogenous hematopoiesis contributes significantly to the favorable outcome following interleukin 1 pretreatment and allogeneic bone marrow transplantation [J].
Herve, V ;
Mabed, M ;
Laithier, V ;
Pavy, JJ ;
Angonin, R ;
Contassot, E ;
Certoux, JM ;
Cahn, JY ;
Herve, P ;
Tiberghien, P .
TRANSPLANTATION, 1996, 61 (04) :673-676